doi: 10.1016/j.cpb.2021.100203 118 BlackHSBoehmFEdgeRTruscottTG
Neuroscience 277, 885901
BPC 157
Presented at: Proceedings of the 4th International Congress on Neuropathic Pain
A decrease in body weight, blood pressure, HbA1c, fasting insulin, insulin resistance, plasma glucagon, total cholesterol, lipids, FPG, SMBG, cardiovascular death, nonfatal stroke, and myocardial infarction are observed with the use of semaglutide in monotherapy or in combination with other antidiabetic drugs
Its research profile makes it relevant for studies focused on melanocortin signaling, pigment-related pathway models, skin biology, cellular response to environmental stressors, and broader neuroendocrine receptor research